Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis

Background The efficacies of second-generation antipsychotic medications in reducing symptoms are reasonably we documented, but their effects on cognition are less clearly understood. Aims To undertake an interim analysis of an open label, 2-year study examining the effects of quetiapine on cognition in patients with a first episode of schizophrenia and related disorders Method Cognitive testing was performed before quetiapine was initiated and repeated after 3,6 and 12 months of treatment. To date, 13 patients have been fully assessed (mean dose 517.9 mg/day; s.d.=225.8). Results Statistically significant improvement was noted on measures of attention (Continuous Performance Test; CPT), verbal productivity (Verbal Fluency Test) and executive function (Object AlternationTest) after 6 and 12 months of treatment. For the CPT, improvement was also noted after 3 months of treatment. Conclusions During treatment for I year with quetiapine, cognitive performance was improved in young patients with psychosis. Continued controlled investigations of the effects of quetiapine on cognition are desirable. Declaration of interest Partial support from AstraZeneca (unrestricted grant) and the Department of Health, Province of Nova Scotia.